Tillkännagivande • Aug 19
Jubilant Ingrevia Limited (NSEI:JUBLINGREA) entered into a binding agreement to acquire 40% stake in Zettaone Technologies for INR 1.9 billion. Jubilant Ingrevia Limited (NSEI:JUBLINGREA) entered into a binding agreement to acquire 40% stake in Zettaone Technologies for INR 1.9 billion on August 18, 2026. A cash consideration of INR 1.89 billion will be paid by Jubilant Ingrevia Limited. As part of consideration, INR 1.89 billion is paid towards common equity of Zettaone Technologies. Following completion of the proposed acquisition, Zettaone Technologies will become an associate company of Jubilant Ingrevia Limited.
For the period ending March 31, 2026, Zettaone Technologies reported total revenue of INR 981 million. The acquisition is proposed to be completed in two tranches, with the first tranche expected to close by November 2026 and the second tranche is expected to close by September 2027. Tillkännagivande • Jul 30
Jubilant Ingrevia Limited, Annual General Meeting, Aug 26, 2026 Jubilant Ingrevia Limited, Annual General Meeting, Aug 26, 2026, at 15:00 Indian Standard Time. Reported Earnings • Jul 23
First quarter 2027 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2027 results: EPS: ₹6.70 (up from ₹4.75 in 1Q 2026). Revenue: ₹13.1b (up 26% from 1Q 2026). Net income: ₹1.06b (up 41% from 1Q 2026). Profit margin: 8.1% (up from 7.2% in 1Q 2026). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) missed analyst estimates by 1.8%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Jul 13
Jubilant Ingrevia Limited to Report Q1, 2027 Results on Jul 22, 2026 Jubilant Ingrevia Limited announced that they will report Q1, 2027 results on Jul 22, 2026 Declared Dividend • May 29
Final dividend of ₹2.50 announced Dividend of ₹2.50 is the same as last year. Ex-date: 24th July 2026 Payment date: 1st January 1970 Dividend yield will be 0.8%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (28% earnings payout ratio) and cash flows (35% cash payout ratio). The dividend has increased by an average of 70% per year over the past 5 years and payments have been stable during that time. EPS is expected to grow by 92% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • May 27
Full year 2026 earnings: Revenues and EPS in line with analyst expectations Full year 2026 results: EPS: ₹17.59 (up from ₹15.89 in FY 2025). Revenue: ₹44.3b (up 6.0% from FY 2025). Net income: ₹2.78b (up 11% from FY 2025). Profit margin: 6.3% (up from 6.0% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst expectations. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • May 26
Jubilant Ingrevia Limited Recommends Final Dividend for the Financial Year Ended March 31, 2026 Jubilant Ingrevia Limited at its AGM held on May 26, 2026 recommended final dividend of 250% i.e. INR 2.50 (Rupees Two and Fifty Paise) per equity share of INR 1 each for the financial year ended March 31, 2026. The dividend, if approved by the shareholders, will be paid /dispatched within 30 days from the date of the Annual General Meeting (AGM). Fixed July 24, 2026, as the record date for the purpose of payment of final dividend. Tillkännagivande • Apr 29
Jubilant Ingrevia Limited to Report Q4, 2026 Results on May 26, 2026 Jubilant Ingrevia Limited announced that they will report Q4, 2026 results on May 26, 2026 Declared Dividend • Feb 06
Dividend of ₹2.50 announced Dividend of ₹2.50 is the same as last year. Ex-date: 10th February 2026 Payment date: 4th March 2026 Dividend yield will be 0.8%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by earnings (15% earnings payout ratio) but not covered by cash flows (280% cash payout ratio). The dividend has increased by an average of 70% per year over the past 5 years and payments have been stable during that time. EPS is expected to grow by 85% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Feb 05
Third quarter 2026 earnings released: EPS: ₹2.97 (vs ₹4.39 in 3Q 2025) Third quarter 2026 results: EPS: ₹2.97 (down from ₹4.39 in 3Q 2025). Revenue: ₹10.6b (flat on 3Q 2025). Net income: ₹469.0m (down 32% from 3Q 2025). Profit margin: 4.4% (down from 6.6% in 3Q 2025). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Tillkännagivande • Jan 19
Jubilant Ingrevia Limited to Report Q3, 2026 Results on Feb 04, 2026 Jubilant Ingrevia Limited announced that they will report Q3, 2026 results on Feb 04, 2026 Buy Or Sell Opportunity • Dec 09
Now 22% overvalued Over the last 90 days, the stock has fallen 4.8% to ₹681. The fair value is estimated to be ₹557, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 6.4% over the last 3 years. Earnings per share has declined by 11%. Revenue is forecast to grow by 35% in 2 years. Earnings are forecast to grow by 69% in the next 2 years. Reported Earnings • Oct 28
Second quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2026 results: EPS: ₹4.40 (up from ₹3.73 in 2Q 2025). Revenue: ₹11.3b (up 8.3% from 2Q 2025). Net income: ₹694.7m (up 18% from 2Q 2025). Profit margin: 6.1% (up from 5.6% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 2.2%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Tillkännagivande • Oct 13
Jubilant Ingrevia Limited to Report Q2, 2026 Results on Oct 27, 2025 Jubilant Ingrevia Limited announced that they will report Q2, 2026 results on Oct 27, 2025 Price Target Changed • Aug 17
Price target increased by 7.0% to ₹956 Up from ₹894, the current price target is an average from 3 analysts. New target price is 36% above last closing price of ₹701. Stock is up 9.0% over the past year. The company is forecast to post earnings per share of ₹20.10 for next year compared to ₹15.89 last year. Tillkännagivande • Aug 04
Jubilant Ingrevia Limited, Annual General Meeting, Aug 29, 2025 Jubilant Ingrevia Limited, Annual General Meeting, Aug 29, 2025, at 15:00 Indian Standard Time. Price Target Changed • Aug 04
Price target increased by 8.3% to ₹968 Up from ₹894, the current price target is an average from 3 analysts. New target price is 28% above last closing price of ₹755. Stock is up 24% over the past year. The company is forecast to post earnings per share of ₹19.95 for next year compared to ₹15.89 last year. Reported Earnings • Aug 01
First quarter 2026 earnings: EPS exceeds analyst expectations First quarter 2026 results: EPS: ₹4.75 (up from ₹3.08 in 1Q 2025). Revenue: ₹10.4b (up 1.3% from 1Q 2025). Net income: ₹751.0m (up 54% from 1Q 2025). Profit margin: 7.2% (up from 4.8% in 1Q 2025). The increase in margin was primarily driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 10%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings. Tillkännagivande • Jul 23
Jubilant Ingrevia Limited to Report Q1, 2026 Results on Jul 31, 2025 Jubilant Ingrevia Limited announced that they will report Q1, 2026 results on Jul 31, 2025 New Risk • Jun 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Declared Dividend • May 15
Final dividend of ₹2.50 announced Dividend of ₹2.50 is the same as last year. Ex-date: 25th July 2025 Payment date: 1st January 1970 Dividend yield will be 0.7%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by both earnings (38% earnings payout ratio) and cash flows (56% cash payout ratio). The dividend has increased by an average of 94% per year over the past 4 years and payments have been stable during that time. EPS is expected to grow by 122% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • May 14
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: ₹15.89 (up from ₹11.56 in FY 2024). Revenue: ₹42.2b (up 1.9% from FY 2024). Net income: ₹2.51b (up 37% from FY 2024). Profit margin: 6.0% (up from 4.4% in FY 2024). Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) also missed analyst estimates by 4.0%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Mar 10
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹671, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 27x in the Chemicals industry in India. Total returns to shareholders of 51% over the past three years. Price Target Changed • Mar 02
Price target increased by 9.4% to ₹895 Up from ₹818, the current price target is an average from 3 analysts. New target price is 45% above last closing price of ₹617. Stock is up 27% over the past year. The company is forecast to post earnings per share of ₹16.53 for next year compared to ₹11.56 last year. Declared Dividend • Jan 30
Dividend of ₹2.50 announced Dividend of ₹2.50 is the same as last year. Ex-date: 3rd February 2025 Payment date: 26th February 2025 Dividend yield will be 0.7%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (19% earnings payout ratio) and cash flows (38% cash payout ratio). The dividend has increased by an average of 94% per year over the past 4 years and payments have been stable during that time. EPS is expected to grow by 70% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Jan 29
Third quarter 2025 earnings: EPS exceeds analyst expectations Third quarter 2025 results: EPS: ₹4.39 (up from ₹2.44 in 3Q 2024). Revenue: ₹10.7b (up 10% from 3Q 2024). Net income: ₹693.8m (up 80% from 3Q 2024). Profit margin: 6.5% (up from 4.0% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 9.7%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Tillkännagivande • Jan 28
Jubilant Ingrevia Limited Declares Interim Dividend for the Financial Year 2024-25, Payable on or Before February 26, 2025 Jubilant Ingrevia Limited announced that at the board meeting held on January 28, 2025 declared an Interim Dividend of INR 2.50 per equity share of INR 1 each on the paid-up Equity Share capital of the Company for the Financial Year 2024-25. The Board has fixed February 3, 2025 as `Record Date' for the purpose of ascertaining eligibility of the shareholders for payment of Interim Dividend. The Interim Dividend will be paid/dispatched on or before February 26, 2025. Valuation Update With 7 Day Price Move • Jan 13
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹699, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 29x in the Chemicals industry in India. Total returns to shareholders of 13% over the past three years. Valuation Update With 7 Day Price Move • Nov 29
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹785, the stock trades at a forward P/E ratio of 42x. Average forward P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 38% over the past three years. Board Change • Nov 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 10 experienced directors. No highly experienced directors. CEO, MD & Director Deepak Jain was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 25
Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2025 results: EPS: ₹3.73 (up from ₹3.64 in 2Q 2024). Revenue: ₹10.5b (up 2.5% from 2Q 2024). Net income: ₹590.0m (up 2.6% from 2Q 2024). Profit margin: 5.6% (in line with 2Q 2024). Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) exceeded analyst estimates by 9.7%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. New Risk • Sep 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.0% average weekly change). Profit margins are more than 30% lower than last year (4.3% net profit margin). Tillkännagivande • Sep 03
Jubilant Ingrevia Limited Announces Resignation of Subhra Jyoti Roy as Senior VP - Agrochemicals Jubilant Ingrevia Limited informed that Mr. Subhra Jyoti Roy has tendered his resignation as Senior VP - Agrochemicals of the Company effective from close of business hours of September 3, 2024. Resigned as got new job opportunity. Tillkännagivande • Aug 30
Jubilant Ingrevia Limited Approves Final Dividend for the Financial Year Ended March 31, 2024 Jubilant Ingrevia Limited at its AGM approved to declare final dividend of INR 2.50 per equity shares of INR 1 each, for the financial year ended March 31, 2024. Price Target Changed • Jul 18
Price target increased by 11% to ₹622 Up from ₹559, the current price target is an average from 3 analysts. New target price is 11% above last closing price of ₹563. Stock is up 37% over the past year. The company is forecast to post earnings per share of ₹18.75 for next year compared to ₹11.56 last year. Reported Earnings • Jul 17
First quarter 2025 earnings: EPS and revenues miss analyst expectations First quarter 2025 results: EPS: ₹3.08 (down from ₹3.63 in 1Q 2024). Revenue: ₹10.2b (down 4.7% from 1Q 2024). Net income: ₹487.4m (down 15% from 1Q 2024). Profit margin: 4.8% (down from 5.4% in 1Q 2024). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 9.4%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in India. Tillkännagivande • Jul 10
Jubilant Ingrevia Limited to Report Q1, 2025 Results on Jul 16, 2024 Jubilant Ingrevia Limited announced that they will report Q1, 2025 results on Jul 16, 2024 Reported Earnings • May 15
Full year 2024 earnings released: EPS: ₹11.56 (vs ₹19.34 in FY 2023) Full year 2024 results: EPS: ₹11.56 (down from ₹19.34 in FY 2023). Revenue: ₹41.7b (down 13% from FY 2023). Net income: ₹1.83b (down 41% from FY 2023). Profit margin: 4.4% (down from 6.4% in FY 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Tillkännagivande • May 15
Jubilant Ingrevia Limited Recommends A Final Dividend for the Financial Year Ended March 31, 2024 The board of directors of Jubilant Ingrevia Limited at their meeting held on May 14, 2024, have recommended a final dividend of 250% i.e. Rs. 2.50/- (Rupees Two and Fifty Paise) per equity share of Re. 1 each for the financial year ended March 31, 2024. The dividend, if approved by the shareholders, will be paid /dispatched within 30 days from the date of the Annual General Meeting. The record date for the purpose of payment of final dividend, if declared, shall be Friday, August 2, 2024. Valuation Update With 7 Day Price Move • Apr 10
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹543, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 74% over the past three years. Upcoming Dividend • Feb 02
Upcoming dividend of ₹2.50 per share at 1.2% yield Eligible shareholders must have bought the stock before 09 February 2024. Payment date: 28 February 2024. Payout ratio is a comfortable 38% but the company is not cash flow positive. Trailing yield: 1.2%. Within top quartile of Indian dividend payers (1.1%). Higher than average of industry peers (0.8%). Reported Earnings • Jan 31
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2024 results: EPS: ₹2.44 (down from ₹5.75 in 3Q 2023). Revenue: ₹9.75b (down 16% from 3Q 2023). Net income: ₹385.6m (down 58% from 3Q 2023). Profit margin: 4.0% (down from 7.9% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) missed analyst estimates by 13%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India. Tillkännagivande • Jan 30
Jubilant Ingrevia Limited Approves Interim Dividend for the Financial Year 2023-24, Payable on or Before February 28, 2024 Jubilant Ingrevia Limited announced that at the Board of Directors of the Company at its meeting held January 30, 2024, declared an Interim Dividend of INR 2.50 per equity share of INR 1 each on the paid-up Equity Share capital of the Company for the Financial Year 2023-24. Further, in terms of Regulation 42 of the Listing Regulations, the Board has fixed February 9, 2024 as `Record Date' for the purpose of ascertaining eligibility of the shareholders for payment of Interim Dividend. The Interim Dividend will be paid/dispatched on or before February 28, 2024. Tillkännagivande • Jan 18
Jubilant Ingrevia Limited to Report Q3, 2024 Results on Jan 30, 2024 Jubilant Ingrevia Limited announced that they will report Q3, 2024 results on Jan 30, 2024 Reported Earnings • Nov 02
Second quarter 2024 earnings released: EPS: ₹3.64 (vs ₹5.31 in 2Q 2023) Second quarter 2024 results: EPS: ₹3.64 (down from ₹5.31 in 2Q 2023). Revenue: ₹10.3b (down 21% from 2Q 2023). Net income: ₹574.9m (down 32% from 2Q 2023). Profit margin: 5.6% (down from 6.5% in 2Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Chemicals industry in India. Tillkännagivande • Oct 28
Jubilant Ingrevia Limited Announces Change in Management Jubilant Ingrevia Limited informed following change in the Senior Management Team of the Company: Mr. Gosaliya Chintan Tarunkumar has tendered his resignation as Sr. VP - Chemicals Intermediates for pursuing his interest outside the organization, the resignation letter is enclosed herewith. As a result, he will cease to be a Sr. VP - Chemicals Intermediates with effect from close of business hour October 27, 2023. Mr. Himanshu Dhapolav has promoted as SBU Head - Acetyls with effect from October 27, 2023. Himanshu completed B.Tech. (Chemical) in 2002 and Master in Management Studies from Mumbai University in 2005. His earlier stints have been with Asian Paints, Anuvi Chemicals, Ameya Dyechem, Galaxy Surfactants and Deepak Nitrite. He has about 20 years of experience, of which the last 2 years have been in Jubilant Ingrevia. During this time, Himanshu has handled international sales, managed large customer accounts, and demonstrated excellent customer management skills. Reported Earnings • Jul 28
First quarter 2024 earnings: EPS and revenues miss analyst expectations First quarter 2024 results: EPS: ₹3.63 (down from ₹4.99 in 1Q 2023). Revenue: ₹10.8b (down 7.8% from 1Q 2023). Net income: ₹575.9m (down 28% from 1Q 2023). Profit margin: 5.4% (down from 6.8% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 3.8%. Earnings per share (EPS) also missed analyst estimates by 9.3%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Chemicals industry in India. Tillkännagivande • Jul 18
Jubilant Ingrevia Limited to Report Q1, 2024 Results on Jul 26, 2023 Jubilant Ingrevia Limited announced that they will report Q1, 2024 results on Jul 26, 2023 Price Target Changed • May 18
Price target decreased by 11% to ₹752 Down from ₹846, the current price target is an average from 4 analysts. New target price is 92% above last closing price of ₹392. Stock is down 11% over the past year. The company is forecast to post earnings per share of ₹25.15 for next year compared to ₹19.34 last year. Reported Earnings • May 17
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: ₹19.34 (down from ₹29.98 in FY 2022). Revenue: ₹48.1b (down 2.9% from FY 2022). Net income: ₹3.08b (down 36% from FY 2022). Profit margin: 6.4% (down from 9.6% in FY 2022). Revenue missed analyst estimates by 4.3%. Earnings per share (EPS) also missed analyst estimates by 19%. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in India. Tillkännagivande • May 10
Jubilant Ingrevia Limited to Report Q4, 2023 Results on May 16, 2023 Jubilant Ingrevia Limited announced that they will report Q4, 2023 results on May 16, 2023 Upcoming Dividend • Feb 03
Upcoming dividend of ₹2.50 per share at 1.0% yield Eligible shareholders must have bought the stock before 10 February 2023. Payment date: 01 March 2023. Payout ratio is a comfortable 25% but the company is not cash flow positive. Trailing yield: 1.0%. Lower than top quartile of Indian dividend payers (1.6%). Higher than average of industry peers (0.9%). Reported Earnings • Feb 01
Third quarter 2023 earnings released: EPS: ₹5.75 (vs ₹4.31 in 3Q 2022) Third quarter 2023 results: EPS: ₹5.75 (up from ₹4.31 in 3Q 2022). Revenue: ₹11.7b (down 10% from 3Q 2022). Net income: ₹915.3m (up 33% from 3Q 2022). Profit margin: 7.9% (up from 5.3% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India. Tillkännagivande • Jan 31
Jubilant Ingrevia Limited Approves Interim Dividend for the Financial Year 2022-2023, payable on or before March 1, 2023 Jubilant Ingrevia Limited Board of Directors at its meeting held January 31, 2023, approved the following: Board has declared an Interim Dividend of INR 2.50 per equity share of Re. 1 each on the paid-up Equity Share capital of the Company for the Financial Year 2022-2023. the Board has fixed February 10, 2023 as ' Record date and Interim Dividend will be paid/dispatched on or before March 1, 2023. Tillkännagivande • Jan 24
Jubilant Ingrevia Limited to Report Q3, 2023 Results on Jan 31, 2023 Jubilant Ingrevia Limited announced that they will report Q3, 2023 results on Jan 31, 2023 Price Target Changed • Nov 16
Price target increased to ₹980 Up from ₹640, the current price target is an average from 3 analysts. New target price is 72% above last closing price of ₹570. Stock is down 7.4% over the past year. The company is forecast to post earnings per share of ₹26.30 for next year compared to ₹29.98 last year. Board Change • Nov 16
High number of new and inexperienced directors There are 11 new directors who have joined the board in the last 3 years. The company's board is composed of: 11 new directors. 1 experienced director. No highly experienced directors. CEO, MD & Executive Director Rajesh Srivastava is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Oct 21
Second quarter 2023 earnings released: EPS: ₹5.31 (vs ₹4.31 in 2Q 2022) Second quarter 2023 results: EPS: ₹5.31 (up from ₹4.31 in 2Q 2022). Revenue: ₹13.0b (flat on 2Q 2022). Net income: ₹842.8m (up 23% from 2Q 2022). Profit margin: 6.5% (up from 5.3% in 2Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India. Tillkännagivande • Oct 13
Jubilant Ingrevia Limited to Report Q2, 2023 Results on Oct 20, 2022 Jubilant Ingrevia Limited announced that they will report Q2, 2023 results on Oct 20, 2022 Tillkännagivande • Sep 27
Jubilant Ingrevia Limited Declares Dividend for the Financial Year Ended March 31, 2022 Jubilant Ingrevia Limited at its 3rd annual general meeting held on September 26, 2022, Declaration of final dividend of INR 2.50 per equity shares, for the financial year ended March 31, 2022. Buying Opportunity • Sep 24
Now 20% undervalued Over the last 90 days, the stock is up 3.9%. The fair value is estimated to be ₹640, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 184% over the last year. Earnings per share has grown by 5.7%. Revenue is forecast to grow by 25% in 2 years. Earnings is forecast to grow by 47% in the next 2 years. Upcoming Dividend • Aug 16
Upcoming dividend of ₹2.50 per share Eligible shareholders must have bought the stock before 23 August 2022. Payment date: 25 October 2022. Payout ratio is a comfortable 21% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of Indian dividend payers (1.7%). Higher than average of industry peers (0.7%). Reported Earnings • Aug 07
First quarter 2023 earnings released First quarter 2023 results: EPS: ₹4.99. Revenue: ₹11.8b (flat on 1Q 2022). Net income: ₹793.8m (up ₹793.8m from 1Q 2022). Profit margin: 6.8% (up from null in 1Q 2022). Over the next year, revenue is forecast to grow 8.0%, compared to a 14% growth forecast for the industry in India. Tillkännagivande • Jul 30
Jubilant Ingrevia Limited to Report Q1, 2023 Results on Aug 05, 2022 Jubilant Ingrevia Limited announced that they will report Q1, 2023 results on Aug 05, 2022 Valuation Update With 7 Day Price Move • Jun 27
Investor sentiment improved over the past week After last week's 20% share price gain to ₹498, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 25x in the Chemicals industry in India. Total loss to shareholders of 7.4% over the past year. Major Estimate Revision • May 19
Consensus forecasts updated The consensus outlook for 2023 has been updated. 2023 revenue forecast increased from ₹44.6b to ₹51.8b. EPS estimate fell from ₹31.20 to ₹30.30. Net income forecast to grow 949% next year vs 24% growth forecast for Chemicals industry in India. Consensus price target of ₹1,006 unchanged from last update. Share price rose 3.9% to ₹438 over the past week. Price Target Changed • Apr 27
Price target increased to ₹893 Up from ₹640, the current price target is provided by 1 analyst. New target price is 80% above last closing price of ₹495. Stock is up 49% over the past year. The company is forecast to post earnings per share of ₹35.80 for next year compared to ₹20.77 last year. Board Change • Apr 27
High number of new and inexperienced directors There are 12 new directors who have joined the board in the last 3 years. The company's board is composed of: 12 new directors. No experienced directors. No highly experienced directors. President & Chief of Operations and Whole-Time Director Anant Pande is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Mar 31
High number of new and inexperienced directors There are 12 new directors who have joined the board in the last 3 years. The company's board is composed of: 12 new directors. No experienced directors. No highly experienced directors. President & Chief of Operations and Whole-Time Director Anant Pande is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Tillkännagivande • Feb 03
Jubilant Ingrevia Limited Declares the Interim Dividend for the Financial Year 2021-22, Payable on or Before March 2, 2022 Jubilant Ingrevia Limited declared the Interim Dividend of INR 2.50 per equity share of Re. 1 each on the paid-up Equity Share capital of the Company for the Financial Year 2021-22. In terms of Regulation 42 of the Listing Regulations, the Board has fixed February 11, 2022 as the `Record Date' for the purpose of ascertaining eligibility of the shareholders for payment of Interim Dividend. The Interim Dividend will be paid/dispatched on or before March 2, 2022. 
